WuXi Biologics (Cayman) Inc

02269

Company Profile

  • Business description

    WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

  • Contact

    No. 108, Meiliang Road
    Mashan Binhu District
    Wuxi214092
    CHN

    T: +86 51085353482

    https://www.wuxibiologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    12,435

WuXi Biologics (Cayman) Inc News & Analysis

stocks

Chinese biotech: Buy the dip?

Morningstar looks at two diversified Chinese biotech names.
stocks

3 top stocks for Asia

Fund managers say these are the themes to consider when looking for stocks in the Asia region

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,780.304.80-0.05%
CAC 408,007.62115.941.47%
DAX 4021,902.42316.491.47%
Dow JONES (US)44,747.63125.65-0.28%
FTSE 1008,727.28103.991.21%
HKSE20,972.2280.600.39%
NASDAQ19,791.9999.660.51%
Nikkei 22538,841.99224.54-0.57%
NZX 50 Index12,902.1957.600.45%
S&P 5006,083.5722.090.36%
S&P/ASX 2008,511.409.30-0.11%
SSE Composite Index3,280.369.700.30%

Market Movers